Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118663 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT01118663 is a Phase 3 study that was terminated before completion, run by Cumberland Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT01118663, a Phase 3 study, was terminated before completion, sponsored by Cumberland Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
Interventions
- DRUG Acetadote
- DRUG Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118663
The ClinicalTrials.gov registry entry for NCT01118663 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acetadote is the first listed.
NCT01118663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118663 about?
NCT01118663 is a clinical study titled "Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection". The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
What is the current status of trial NCT01118663?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2010-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01118663?
The interventions under investigation include: Acetadote (DRUG), Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) (DRUG).
Who is sponsoring clinical trial NCT01118663?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.